Transplantation News CME/CE
- FDA Safety Changes: DepoDur, Neoral, Lexiva
- FDA Approvals: Zirgan, Prism HIV, Valturna
- New Guidelines Help Primary Care Doctors Treat Liver Transplant Recipients
- FDA Approvals: Azelastine, Guanfacine, Valganciclovir
- FDA Safety Changes: Strattera, Aptivus, CellCept
- Drug-Induced Acute Liver Failure Very Rare, but Can Be Fatal
- Lung Transplantation May Be Used With Caution in Older Patients
- Criteria Identified to Help Predict Survival Benefit From Combined Heart/Kidney Transplantation
- Hyponatremia May Predict Mortality Among Patients Awaiting Liver Transplant
- Complete Steroid Avoidance Worsens Rather Than Improves Liver Transplant Outcome
- Sex of Kidney Donor May Affect Graft Success
- Guidelines for Hepatitis C in Chronic Kidney Disease Issued
- FDA Safety Changes: Abilify, Sarafem, Cubicin, Invanz, Arava
- FDA Safety Changes: Cymbalta, Crestor, Rapamune
- FDA Approvals: Flo-Pred, Recothrom, Intelence
- Unretrieved Device Fragments Cause More Than 1000 Injuries Annually
- Coronary Angiography Does Not Accelerate GFR Decline in Late-Stage CKD
- Donor Risk Must Be Factored Into Transplant Decisions
- USPSTF Issues Statement on Routine Screening for Lipid Disorders in Young People
- CDC Revises Guidelines for Infection Prevention in Hospitals and Healthcare Settings